@arcinstitute: STING agonists can shrink tumors and make them visible to the immune system, but high doses become toxic to T cells. Co…
Summary
Researchers at the Arc Institute identified that STING agonists enter and kill T cells through the SLC7A1 arginine transporter, explaining the toxicity at high doses while still showing anti-tumor effects.
View Cached Full Text
Cached at: 06/27/26, 03:52 AM
STING agonists can shrink tumors and make them visible to the immune system, but high doses become toxic to T cells. Core Investigator @li_lingyin and team have identified SLC7A1, the T cell arginine transporter, as the primary route by which these agonists enter and kill T https://t.co/7QFM5rLuFf
Similar Articles
@smaksked: Bizarre CRISPR enzyme kills cancer cells by shredding their DNA Early tests suggest the protein can be aimed at targets…
A new CRISPR-based enzyme shows promise in early tests for targeting tumor-causing mutations and shredding cancer DNA.
How a Gemma model helped discover a new potential cancer therapy pathway
Google DeepMind and Yale released C2S-Scale, a 27B parameter foundation model built on Gemma for single-cell analysis that discovered a promising drug combination (silmitasertib and interferon) to enhance immune visibility of "cold" tumors, with predictions validated through experimental confirmation.
Venom and Hot Peppers Offer a Key to Killing Resistant Bacteria
Researchers developed new antibiotics from scorpion venom and habanero peppers, demonstrating efficacy against resistant bacteria including tuberculosis strains, with ongoing work towards clinical trials.
Colon cancer’s invisibility cloak removed by eliminating a single gene - a fundamental breakthrough. The result was 100% eradication of tumours when paired with immunotherapy treatment in mouse models.
New University of Calgary research shows that knocking out a single gene makes colon cancer cells visible to the immune system, and when combined with immunotherapy, leads to 100% tumor eradication in mouse models, offering a potential new approach for treating colorectal cancer.
@ScienceMagazine: Drug candidates that form covalent bonds with their targets were historically avoided because of toxicity concerns. How…
A new Science study reports streamlined access to an underexplored covalent warhead type with well-tempered reactivity, enabling practical use in drug discovery.